Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination Wi | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  24902 of 24955  at  6/30/2020 4:20:32 PM  by

duckduffer


 In response to msg 24896 by  alias geo
view thread
Strong Buy

Re: Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer

Solid market response to this announcement, a couple of things do stand out.
First, all partners are invested.
"The trial is sponsored by Exelixis and co-funded by Roche, Ipsen and Takeda Pharmaceutical Company Limited. "
Second, the launching of the trial confirms that all data including the newest cohorts added to Cosmic 021 continues to be compelling. Some investors may have been waiting to see more data. This announcement pretty much derisks any concern the data may not have held up with more patients and more time.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 18     Views: 306
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
24906 Re: Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer JoeFlow 7 6/30/2020 8:22:20 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...